SEOM clinical guidelines for the treatment of pancreatic cancer

被引:0
作者
Carlos Gómez-Martín
Manuel Hidalgo
Josep Tabernero
Dolores Isla
机构
[1] Hospital Universitario 12 de Octubre,Servicio de Oncología Médica
[2] Centro Integral Oncológico Clara Campal,Servicio de Oncología Médica
[3] Programa de Investigación Clínica,Servicio de Oncología Médica
[4] CNIO,Servicio de Oncología Médica
[5] Hospital Universitario Vall d’Hebron,undefined
[6] Hospital Lozano Blesa,undefined
来源
Clinical and Translational Oncology | 2011年 / 13卷
关键词
Pancreatic cancer; Treatment; Diagnosis; Guidelines;
D O I
暂无
中图分类号
学科分类号
摘要
Pancreatic cancer (PC) is one of the main causes of cancer-related death in the United States and Europe. Due to its poor long-term survival, all patients with PC should undergo a comprehensive evaluation by a Multidisciplinary Tumor Committee to establish the best therapeutic strategy. Pathologic PC diagnosis should be made according to the latest WHO classification of malignant tumours and an accurate staging is crucial to assess resectability, determine the extension and, in some cases, reestablish biliary flow. For patients with localised resectable disease the standard treatment option is radical pancreatic resection. The aim of resection is to obtain microscopically negative margins (R0) and also to resect the drainage lymph nodes. In those cases diagnosed with locally advanced unresectable or metastatic PC, palliative bypass of intestinal or biliary obstruction followed by chemotherapy or chemoradiation remains the main palliative treatment option. Since 1997, gemcitabine monotherapy has been considered the standard of care for advanced PC. In recent years new chemotherapy combinations and targeted agents have demonstrated significant antitumoral activity, increasing the armamentarium that can be used against this lethal disease.
引用
收藏
页码:528 / 535
页数:7
相关论文
共 69 条
[1]  
Tran K.T.(2004)Pylorus preserving pancreaticoduodenectomy versus Standard Whipple procedure Ann Surg 240 738-745
[2]  
Smeenk H.G.(2005)Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection: long term results Br J Surg 92 547-556
[3]  
van Eijck C.H.(2004)A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 1200-1210
[4]  
Seiler C.A.(2007)Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 267-277
[5]  
Wagner M.(2009)ESPAC-3(v2): a multicenter, international, openlabel, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5FU/FA) versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma J Clin Oncol 27 203-3502
[6]  
Bachmann T.(2006)RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma J Clin Oncol 24 4007-3495
[7]  
Neoptolemos J.P.(2008)Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head J Clin Oncol 2 3496-2277
[8]  
Stocken D.D.(2008)Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 3487-2413
[9]  
Friess H.(2008)A randomized phase III study of Gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 J Clin Oncol 26 4506-3622
[10]  
Oettle H.(2009)Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review J Clin Oncol 27 2269-3610